Key Highlights

  • ImmuPharma rose 12.50% to 4.5p after selecting Thermo Fisher Scientific's Patheon business as drug-product CDMO for Kapiglucagon.
  • The appointment is a genuine chemistry, manufacturing and controls milestone, but Kapiglucagon remains pre-clinical and any US 505(b)(2) route needs FDA alignment.
  • A £6.47 million April fundraise improved funding for the pipeline but issued more than 107 million shares, making dilution an essential part of the analysis.

ImmuPharma plc (LSE: IMM) advanced 12.50% to 4.5p after a tangible development milestone for its diabetes programme. On 22 July 2026, the company selected Thermo Fisher Scientific's Patheon services as drug-product contract development and manufacturing organisation for Kapiglucagon. The appointment followed the earlier selection of Bachem for active pharmaceutical ingredient manufacturing.

The news puts the AIM biotech back on investors' radar because it turns an experimental asset into a more organised development programme. It does not, however, prove clinical efficacy or create near-term product revenue.

Company Overview

ImmuPharma is a specialist drug-discovery and development company focused on peptide-based therapies. Its lead platform is P140, being developed for autoimmune diseases with a companion diagnostic known as Type M. Kapiglucagon is a proprietary glucagon prodrug aimed at Type 1 diabetes applications, including potential use in dual-hormone artificial-pancreas systems.

The group is pre-commercial. It funds research, manufacturing, regulatory preparation and intellectual property while seeking partners that can finance larger clinical programmes. Its valuation therefore responds strongly to scientific, manufacturing, regulatory and licensing milestones.

Why The Shares Are Attracting Attention

A credible manufacturer is necessary before an investigational medicine can enter clinical development. Thermo Fisher will support the drug-product workstream, while Bachem supports the active ingredient. Together, these appointments strengthen the chemistry, manufacturing and controls package needed for regulatory interactions and an Investigational New Drug application.

ImmuPharma is evaluating whether Kapiglucagon could use the US 505(b)(2) pathway, which may allow reliance on existing information about native glucagon. The route could be more efficient than a completely new drug application, but the FDA must agree and can still require substantial non-clinical, clinical and manufacturing evidence.

Latest Financial Performance

For the year ended 31 December 2025, ImmuPharma reported a loss after tax of £1.8 million, improved from £2.5 million in 2024. Research and development expense was £1.3 million, administrative expense £1.0 million and basic loss per share 0.37p.

The operating loss was £2.5 million, with the lower after-tax loss helped by finance income and an R&D tax credit. These are development-stage accounts: there is no recurring product revenue against which to measure margins. The important questions are cash burn, programme prioritisation and whether external partners validate the assets.

Operational Performance

P140 remains the core value driver. The company is developing it alongside the Type M diagnostic, intended to identify patients who may be more likely to respond. In April 2026, ImmuPharma reported progress on its UK patent examination and supporting study data, while continuing discussions with potential commercial partners.

Kapiglucagon has been accelerated into IND-enabling work. The programme is designed to improve the solubility and formulation stability problems associated with native glucagon. Manufacturing partners, pre-IND preparation and non-clinical studies are necessary steps, but first-in-human testing remains subject to successful execution and regulatory clearance.

Balance Sheet, Cash Flow And Funding

Cash and cash equivalents were £1.4 million at 31 December 2025, compared with £0.2 million a year earlier. Net cash used in operating activities was about £2.68 million. The year-end position alone would have provided limited runway for two active programmes.

On 7 April 2026, ImmuPharma completed a £6.47 million fundraise at 6p. It comprised a £6 million Lanstead subscription for 100 million shares and a retail offer of approximately £468,747 for 7.81 million shares. The cash supports development, but the enlarged share count means future value is spread across more ordinary shares.

Recent Announcements And Strategic Developments

The Thermo Fisher appointment was the immediate catalyst and followed Bachem's appointment as API manufacturer. This two-part supply chain should help define formulation, analytical methods and production standards. Investors should still watch contract costs, timelines and whether batches meet required specifications.

Management has stated that it aims to complete a value-enhancing P140 licensing transaction in 2026. A partnership could bring non-dilutive funding, expertise and external validation. It is an objective, not a completed deal; economics, territory, development obligations and upfront cash would determine its significance.

Industry And Economic Backdrop

Biotechnology markets reward programmes that address clear unmet need and show a credible path through development. Type 1 diabetes technologies are advancing towards automated insulin delivery, and a stable glucagon formulation could support dual-hormone systems. The commercial opportunity depends on clinical benefit, device integration, manufacturing cost and reimbursement.

Autoimmune drug development is especially difficult because diseases are heterogeneous and previous trials across the sector have produced mixed outcomes. A companion diagnostic may improve patient selection, but it must itself be analytically and clinically validated. Capital markets can also become less supportive when interest rates rise or clinical setbacks increase risk aversion.

Potential Growth Drivers

For Kapiglucagon, growth in value would come from successful IND-enabling studies, constructive FDA feedback, a cleared IND and first-in-human data. A 505(b)(2) route, if accepted, could shorten parts of the programme. A device or diabetes partner could add development and commercial capability.

For P140, the most important driver is a credible licensing agreement supported by the Type M strategy. Strong patent protection, peer-reviewed data and a clearly defined target population could improve negotiating leverage. ImmuPharma's anti-infective assets provide additional optionality but should not distract resources from the leading programmes.

Upcoming Milestones Or Catalysts

Near-term milestones include drug-product and API development work, regulatory preparation for Kapiglucagon and any pre-IND interaction with the FDA. Investors should seek specific timelines, study scope and budget rather than broad statements that the programme is progressing.

For P140, a commercial partnership, patent developments and publication of supporting science would be material. The next financial update should disclose cash, expenditure and how much of the April fundraise remains. Further equity issuance is possible if development advances without a partner.

Principal Risks And Uncertainties

Both leading assets face scientific and clinical failure risk. Manufacturing may uncover stability or scale-up problems, regulators may require more work and trials may not reproduce encouraging laboratory findings. Timelines in drug development are frequently longer than expected.

Funding and dilution are equally important. ImmuPharma has no recurring commercial revenue and may need further capital. Lanstead-style financing can expose receipts to share-price performance, while options and warrants can enlarge the fully diluted share count. Partner discussions may not result in a deal, or terms may transfer a large share of future economics.

Investment Perspective

ImmuPharma has made measurable progress. It has funded the next phase, organised specialist manufacturing for Kapiglucagon and continued the diagnostic-led P140 strategy. The July appointment is more substantive than a promotional update because manufacturing is a prerequisite for clinical development.

The company remains an early-stage biotech, not a healthcare business with established sales. Valuation depends on probabilities across regulation, science, partnering and finance. Investors should treat each milestone as a reduction in one category of risk rather than evidence that all risks have been removed.

Outlook

ImmuPharma (LSE: IMM) broke higher after selecting Thermo Fisher as Kapiglucagon's drug-product CDMO. The move brings the diabetes programme closer to regulatory preparation and has a confirmed company-specific basis. The next tests are successful CMC execution, FDA alignment, clinical entry and a value-adding P140 partnership. The £6.47 million fundraise provides resources, but dilution and future cash needs keep the risk profile high.